{"id":31405,"date":"2025-04-02T17:26:39","date_gmt":"2025-04-02T11:56:39","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=31405"},"modified":"2025-09-26T13:03:13","modified_gmt":"2025-09-26T07:33:13","slug":"latest-breakthroughs-multiple-myeloma-treatment","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/latest-breakthroughs-multiple-myeloma-treatment","title":{"rendered":"Revolutionary Advances and Bright New Horizons in Multiple Myeloma Treatment"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69d17872a44fe\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69d17872a44fe\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/latest-breakthroughs-multiple-myeloma-treatment\/#SARCLISA_Takes_Center_Stage\" >SARCLISA Takes Center Stage<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/latest-breakthroughs-multiple-myeloma-treatment\/#A_New_Era_for_Multiple_Myeloma_Patients\" >A New Era for Multiple Myeloma Patients<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/latest-breakthroughs-multiple-myeloma-treatment\/#April_2025\" >April 2025<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/latest-breakthroughs-multiple-myeloma-treatment\/#March_2025\" >March 2025&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/latest-breakthroughs-multiple-myeloma-treatment\/#February_2025\" >February 2025&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/latest-breakthroughs-multiple-myeloma-treatment\/#January_2025\" >January 2025<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.delveinsight.com\/blog\/latest-breakthroughs-multiple-myeloma-treatment\/#A_Robust_Pipeline\" >A Robust Pipeline<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/www.delveinsight.com\/blog\/latest-breakthroughs-multiple-myeloma-treatment\/#Pioneering_Progress_Transforming_the_Multiple_Myeloma_Treatment_Frontier\" >Pioneering Progress: Transforming the Multiple Myeloma Treatment Frontier<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>Multiple myeloma, a complex blood cancer rooted in the bone marrow, affects <strong>160K people globally<\/strong> <strong>each year<\/strong>, with a <strong>mortality rate<\/strong> of <strong>106K<\/strong>. According to DelveInsight, <strong>nearly 75K new cases<\/strong> were reported across seven major markets in 2023, a figure expected to climb in the coming years. Yet, amid these sobering statistics, a wave of progress is reshaping the multiple myeloma treatment landscape, offering new hope to patients facing this challenging disease.<\/p>\n\n\n\n<p>Traditionally, the fight against <a href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-myeloma-market\">multiple myeloma<\/a> has leaned on chemotherapy and steroids\u2014reliable, if broad, tools. But the story has shifted in recent years, with therapies like <a href=\"https:\/\/www.delveinsight.com\/report-store\/car-t-cell-therapy-for-multiple-myeloma-market\">CAR-T cell therapy<\/a> stepping in to deliver targeted immunotherapy for patients unresponsive to other treatments.<a href=\"https:\/\/www.delveinsight.com\/report-store\/bispecifics-trispecifics-competitive-landscape-and-market-forecast\" class=\"ek-link\"> Bispecific antibodies <\/a>have also emerged, linking immune cells to cancer cells for precise attacks, while genomic studies are uncovering genetic markers to personalize care. These advancements signal a move toward smarter, more tailored solutions.<\/p>\n\n\n\n<p>The approved multiple myeloma drug lineup reflects this evolution. Since 2015, therapies like <strong>NINLARO,<\/strong> the<em> first oral proteasome inhibitor<\/em>, and <strong>EMPLICITI<\/strong>, an immune enhancer, have broadened multiple myeloma treatment options. <strong>DARZALEX<\/strong>, targeting CD38, joined in 2015, followed by <strong>BLENREP <\/strong>in 2020 with its anti-BCMA approach. <strong>TECVAYLI and CARVYKTI <\/strong>arrived in 2022 and <strong>TALVEY <\/strong>in 2023, each adding depth to the arsenal. These multiple myeloma drugs have not only expanded choices but also improved outcomes for patients.<\/p>\n\n\n\n<p>Discover more about the <strong>approved drugs <\/strong>shaping the multiple myeloma treatment landscape \u2014<a href=\"https:\/\/www.delveinsight.com\/blog\/the-changing-landscape-of-multiple-myeloma-therapies-market\"><strong><em>Read Our Blog!<\/em><\/strong><\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-sarclisa-takes-center-stage\"><span class=\"ez-toc-section\" id=\"SARCLISA_Takes_Center_Stage\"><\/span>SARCLISA Takes Center Stage<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>As we discuss approved therapies, one making headlines is <strong>SARCLISA<\/strong>, first approved in <strong>2020 <\/strong>for treating adult patients with multiple myeloma who have received at least two prior therapies. In <strong>September 2024,<\/strong> it earned approval from the FDA in combination with <strong>bortezomib, lenalidomide, and dexamethasone (VRd) <\/strong>as a first-line treatment for<strong> newly diagnosed multiple myeloma (NDMM)<\/strong> patients ineligible for autologous stem cell transplants.<strong> <\/strong><em>Data showed a 40% reduction in disease progression or death compared to VRd alone<\/em><strong><em>\u2014a first for an <\/em><\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/anti-cd38-antibody-pipeline-insight\"><strong><em>anti-CD38 therapy<\/em><\/strong><\/a><strong><em> in this setting.<\/em><\/strong><\/p>\n\n\n\n<p>The momentum continued into <strong>December 2024<\/strong> at the <strong>66th American Society of Hematology (ASH) Annual Meeting <\/strong>in San Diego. Three oral presentations, including results from the IMROZ and GMMG-HD7 phase III studies, highlighted SARCLISA\u2019s ability to deliver deep, durable responses and better long-term outcomes when added to standard NDMM regimens. These findings solidified its growing role.<\/p>\n\n\n\n<p>In January 2025, China\u2019s <strong>National Medical Products Administration (NMPA) <\/strong>approved <strong>SARCLISA <\/strong>with pomalidomide and dexamethasone for patients with at least one prior therapy line, including lenalidomide and a proteasome inhibitor. <strong>A month later, in February 2025,<\/strong> Japan\u2019s <strong>Ministry of Health, Labour and Welfare (MHLW) <\/strong>followed suit, approving SARCLISA with VRd for NDMM based on the IMROZ study. Each approval marks a step forward in global access.<\/p>\n\n\n\n<p>SARCLISA is currently <strong>approved in over 50 countries,<\/strong> including the US, EU, Japan, and China, for multiple indications, and each approval marks a step forward in global access.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-a-new-era-for-multiple-myeloma-patients\"><span class=\"ez-toc-section\" id=\"A_New_Era_for_Multiple_Myeloma_Patients\"><\/span>A New Era for Multiple Myeloma Patients<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The fight against multiple myeloma is far from over, but with each breakthrough, the future becomes more hopeful. The focus is shifting toward personalized medicine, where treatments of multiple myeloma\u200b are tailored to individual disease characteristics, maximizing efficacy while minimizing side effects. As multiple myeloma therapies like <strong>SARCLISA<\/strong> redefine first-line treatment strategies and <strong>emerging options<\/strong> push the boundaries of what\u2019s possible, long-term survival\u2014and even the prospect of a cure\u2014may one day be within reach.<\/p>\n\n\n\n<p>The journey continues, but the path is increasingly well-lit. With new developments unfolding at a rapid pace, let\u2019s explore the most recent breakthroughs shaping the future of the newest treatment for multiple myeloma and how they are transforming patient care.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-april-2025\"><span class=\"ez-toc-section\" id=\"April_2025\"><\/span>April 2025<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>April 2025 has seen significant progress in multiple myeloma and hematologic cancer treatments, with key findings from the <strong>51st Annual EBMT Meeting (March 30 \u2013 April 2, 2025)<\/strong> highlighting the potential of <strong>CAR-T therapy<\/strong> and <strong>novel targeted treatments<\/strong>.<\/p>\n\n\n\n<p>New data from the <strong>phase III CARTITUDE-4 trial (NCT04181827)<\/strong> reinforced the efficacy of <strong>ciltacabtagene autoleucel (cilta-cel; Carvykti)<\/strong> in <a href=\"https:\/\/www.delveinsight.com\/report-store\/relapsing-refractory-multiple-myeloma-market\"><strong>lenalidomide-refractory multiple myeloma<\/strong>.<\/a> Among <strong>evaluable patients, 69% achieved MRD negativity<\/strong> at a <strong>10\u20135 threshold by day 56<\/strong>, rising to <strong>86% at six months<\/strong>. Even in the <strong>intention-to-treat (ITT) population<\/strong>, MRD-negativity rates reached <strong>48% at day 56 and 60% at six months<\/strong>. With an odds ratio (OR) of 13.3 (P &lt; .0001) in the MRD-evaluable group, cilta-cel continues to demonstrate deep and sustained responses, reinforcing its role as a transformative CAR-T therapy. Beyond multiple myeloma, the <strong>phase I AFM28-101 trial (NCT05817058)<\/strong> presented promising early data on AFM28, a novel therapy for <strong>CD123-positive relapsed\/refractory AML<\/strong>.&nbsp;<\/p>\n\n\n\n<p>Also, new data from the <strong>phase III PERSEUS trial (NCT03710603)<\/strong>, presented at the <strong>EBMT Meeting<\/strong>, confirmed that <strong>D-VRd (daratumumab, bortezomib, lenalidomide, and dexamethasone) <\/strong>followed by<strong> daratumumab\/lenalidomide maintenance<\/strong> improved progression-free survival (PFS) and MRD negativity compared to VRd followed by lenalidomide maintenance in transplant-eligible newly diagnosed multiple myeloma. The study showed PFS benefits across all cytogenetic risk groups, including those with high-risk abnormalities, reinforcing D-VRd as a stronger frontline option for newly diagnosed patients.<\/p>\n\n\n\n<p>With cilta-cel setting new benchmarks in multiple myeloma and AFM28 showing early promise in AML, April 2025 marked a significant step toward more effective, long-lasting treatments for patients battling hematologic cancers.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-march-2025-nbsp\"><span class=\"ez-toc-section\" id=\"March_2025\"><\/span>March 2025&nbsp;<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>In March 2025, the <strong>FDA issued its first untitled letter of the year<\/strong>, addressing concerns over the promotional practices of <strong>Edenbridge Pharmaceuticals<\/strong>\u2014now rebranded as <strong>Dexcel Pharma<\/strong>. The notice was sent after the agency reviewed an exhibit booth panel promoting Hemady, an oral formulation of the steroid dexamethasone used in multiple myeloma treatment.<\/p>\n\n\n\n<p>Hemady was designed to reduce pill burden by delivering <strong>20 mg of dexamethasone per tablet<\/strong>, compared to the <strong>4 mg found in some existing formulations<\/strong>. While the exhibit highlighted the drug\u2019s advantages, the FDA found deficiencies in the way data was presented. Following a review prompted by a complaint through the Bad Ad program, the agency took issue with missing information and questioned the robustness of the study supporting some of the claims.<\/p>\n\n\n\n<p>This regulatory action underscores the FDA\u2019s continued vigilance in ensuring accurate and balanced communication around multiple myeloma treatments, reinforcing the importance of comprehensive data disclosure in pharmaceutical promotions.&nbsp;<\/p>\n\n\n\n<p>Also in March, <strong>IASO Biotherapeutics<\/strong> announced that the <strong>Pharmaceutical Administration Bureau of Macau (ISAF)<\/strong> approved the <strong>New Drug Application (NDA) <\/strong>for <strong>Equecabtagene Autoleucel (FUCASO)<\/strong>. This marks the therapy\u2019s <strong>first approval outside Mainland China<\/strong> for <strong>relapsed\/refractory multiple myeloma (R\/RMM)<\/strong> in patients who have received at least three prior treatments, including a proteasome inhibitor and an immunomodulatory agent.<\/p>\n\n\n\n<p>The approval is based on data from the FUMANBA-1 trial (NCT05066646), which demonstrated strong efficacy and a favorable safety profile. The NDA was also recently accepted in Singapore and Hong Kong, further advancing IASO Bio\u2019s goal of expanding global access to its CAR-T therapies.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-february-2025-nbsp\"><span class=\"ez-toc-section\" id=\"February_2025\"><\/span>February 2025&nbsp;<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>In <strong>February 2025<\/strong>, <strong>Opna Bio\u2019s OPN-6602<\/strong>, an <strong>oral small molecule inhibitor of EP300 and CBP<\/strong>, received <strong>Orphan Drug designation (ODD) from the FDA<\/strong> for <strong>multiple myeloma<\/strong>. Currently in a <strong>phase I trial for relapsed\/refractory multiple myeloma<\/strong>, OPN-6602 has shown promise in preclinical studies, achieving 71% tumor suppression as monotherapy and 100% tumor regression in combination with dexamethasone, pomalidomide, or mezigdomide. The company aims to explore its potential in combination therapies to enhance multiple myeloma treatment options\u200b for patients with resistant disease.<\/p>\n\n\n\n<p>Also in <strong>February 2025<\/strong>, <strong>Japan\u2019s Ministry of Health, Labour and Welfare (MHLW)<\/strong> approved <strong>SARCLISA (isatuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd)<\/strong> for newly diagnosed multiple myeloma (NDMM). This decision, based on findings from the IMROZ phase III study, marks SARCLISA\u2019s fourth approved regimen in Japan, further expanding its role in both relapsed\/refractory and frontline treatment settings.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-january-2025\"><span class=\"ez-toc-section\" id=\"January_2025\"><\/span>January 2025<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>In <strong>January 2025<\/strong>, <strong>China\u2019s National Medical Products Administration (NMPA)<\/strong> approved <strong>SARCLISA <\/strong>(isatuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for <strong>newly diagnosed multiple myeloma (NDMM) patients ineligible for transplant<\/strong>. This makes <strong>SARCLISA the first anti-CD38 therapy approved with VRd<\/strong> in this patient population.<\/p>\n\n\n\n<p>The approval is based on findings from the IMROZ phase III study, which demonstrated that Sarclisa-VRd significantly improved progression-free survival (PFS) compared to VRd alone. Notably, this is Sarclisa\u2019s second approval in China within three weeks, following its R\/R multiple myeloma indication on January 13, 2025.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-a-robust-pipeline\"><span class=\"ez-toc-section\" id=\"A_Robust_Pipeline\"><\/span>A Robust Pipeline<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Looking ahead, the <a href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-myeloma-pipeline-insight\">multiple myeloma pipeline<\/a> is bustling with potential. <strong>Arcellx&#8217;s Anito-Cel, Bristol Myers Squibb\/Celgene&#8217;s Mezigdomide, Novartis&#8217;s PHE885, Regeneron Pharmaceuticals&#8217;s REGN5459, Cartesian Therapeutics&#8217;s Descartes-11, Heidelberg Pharma&#8217;s HDP-101, Beigene&#8217;s BGB-11417, Carsgen Therapeutics&#8217;s Zevorcabtagene Autoleucel, C4 Therapeutics&#8217;s CFT7455 <\/strong>are among the contenders, joined by efforts from <strong>Poseida Therapeutics, Ichnos Sciences, Nerviano Medical Sciences, Ascentage Pharma, Ionis Pharmaceuticals, Chongqing Precision Biotech, CRISPR Therapeutics, AstraZeneca, IGM Biosciences, <\/strong>and others. Spanning CAR-T therapies, novel inhibitors, and antibodies, these candidates promise to further transform care.<\/p>\n\n\n\n<p>The multiple myeloma treatment landscape stands at a pivotal moment. With groundbreaking research, expanding access to innovative treatments, and a robust pipeline of novel therapies, patients have more options\u2014and more reasons for optimism\u2014than ever before.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-pioneering-progress-transforming-the-multiple-myeloma-treatment-frontier\"><span class=\"ez-toc-section\" id=\"Pioneering_Progress_Transforming_the_Multiple_Myeloma_Treatment_Frontier\"><\/span>Pioneering Progress: Transforming the Multiple Myeloma Treatment Frontier<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The <a href=\"https:\/\/www.delveinsight.com\/blog\/bispecific-antibodies-for-multiple-myeloma-treatment\">multiple myeloma treatment market<\/a> is a testament to the power of innovation and perseverance. From the global reach of multiple myeloma therapies like SARCLISA, now approved in over 50 countries, to the promising data emerging from trials like CARTITUDE-4 and PERSEUS, the field is advancing at an inspiring pace. The journey that began with traditional tools like chemotherapy and steroids has evolved into a sophisticated narrative of precision medicine\u2014<em>CAR-T therapies, bispecific antibodies, and genomic insights<\/em> are no longer just possibilities but realities, improving lives.<\/p>\n\n\n\n<p>The pipeline, brimming with contenders from<strong> Arcellx, Bristol Myers Squibb, Novartis, <\/strong>and beyond, signals that this progress is far from slowing. Each approval, each trial result, and each regulatory milestone lights the way toward a future where multiple myeloma may not just be managed but potentially overcome. With the newest treatments for multiple myeloma, including cutting-edge CAR-T therapies, bispecific antibodies, and novel targeted agents, patients have more multiple myeloma treatment options\u200b than ever before. For patients, caregivers, and clinicians, this moment offers more than hope\u2014it provides tangible solutions and a clearer path forward. The road ahead remains long, but with every step, the horizon grows brighter, promising a new era of care for those touched by this complex disease.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-myeloma-market\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/05164141\/Multiple-Myeloma-Market-Outlook-and-Insights-1024x194.jpg\" alt=\"\" class=\"wp-image-29009\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/05164141\/Multiple-Myeloma-Market-Outlook-and-Insights-1024x194.jpg 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/05164141\/Multiple-Myeloma-Market-Outlook-and-Insights-300x57.jpg 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/05164141\/Multiple-Myeloma-Market-Outlook-and-Insights-150x28.jpg 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/05164141\/Multiple-Myeloma-Market-Outlook-and-Insights-768x145.jpg 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/05164141\/Multiple-Myeloma-Market-Outlook-and-Insights-1536x291.jpg 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/05164141\/Multiple-Myeloma-Market-Outlook-and-Insights-1568x297.jpg 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/08\/05164141\/Multiple-Myeloma-Market-Outlook-and-Insights.jpg 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<p><strong>Frequently Asked Questions<\/strong><\/p>\n\n\n\n<div class=\"schema-faq wp-block-yoast-faq-block\"><div class=\"schema-faq-section\" id=\"faq-question-1758871926032\"><strong class=\"schema-faq-question\"><strong>What are the most recent major approved therapies for multiple myeloma?<\/strong><\/strong> <p class=\"schema-faq-answer\">Recent advances include SARCLISA (isatuximab) gaining approval in new indications. For example, in 2024, SARCLISA plus VRd (bortezomib, lenalidomide, dexamethasone) was approved as a first-line treatment for newly diagnosed multiple myeloma (NDMM) patients ineligible for stem cell transplant. Also, therapies such as TECVAYLI, CARVYKTI, and TALVEY, as well as anti-BCMA agents like BLENREP, have enriched the treatment arsenal.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1758871936874\"><strong class=\"schema-faq-question\"><strong>What is SARCLISA\u2019s evolving role in multiple myeloma treatment?<\/strong><\/strong> <p class=\"schema-faq-answer\">SARCLISA is becoming a key player. Beyond its earlier indication (after \u22652 prior therapies), in September 2024 it was approved in combination with VRd as a first-line regimen for transplant-ineligible NDMM patients. Data from the IMROZ and GMMG-HD7 phase III studies support its ability to deliver deeper and more durable responses when added to standard regimens.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1758871937509\"><strong class=\"schema-faq-question\"><strong>What are the most promising upcoming therapies in the multiple myeloma pipeline?<\/strong><\/strong> <p class=\"schema-faq-answer\">The pipeline includes various CAR-T therapies, bispecific antibodies, and novel targeted agents. Notable candidates include Anito-Cel (Arcellx), Mezigdomide (BMS \/ Celgene), PHE885 (Novartis), REGN5459 (Regeneron), Descartes-11 (Cartesian Therapeutics), HDP-101 (Heidelberg Pharma), BGB-11417 (Beigene), Zevorcabtagene Autoleucel (Carsgen), CFT7455 (C4 Therapeutics), among others.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1758871937957\"><strong class=\"schema-faq-question\"><strong>Which recent clinical trials have shown significant results, and what metrics are being used?<\/strong><\/strong> <p class=\"schema-faq-answer\">Several trials have delivered important data: CARTITUDE-4 demonstrated that ciltacabtagene autoleucel (Carvykti) induced measurable residual disease (MRD) negativity at a 10\u207b\u2075 threshold in ~69% of evaluable patients by day 56, rising to 86% at six months. The PERSEUS trial showed that D-VRd (daratumumab-VRd) followed by daratumumab\/lenalidomide maintenance improved progression-free survival (PFS) and MRD-negativity compared to VRd + lenalidomide maintenance in transplant-eligible NDMM. This benefit held across different cytogenetic risk groups.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1758871938469\"><strong class=\"schema-faq-question\"><strong>What are the biggest challenges and what future directions are emerging?<\/strong><\/strong> <p class=\"schema-faq-answer\">Challenges include ensuring access to CAR-T therapies world-wide, managing cost, achieving durable responses especially in high-risk patient populations, and optimizing sequencing of therapies. Future directions involve precision medicine approaches (tailoring treatments based on genetic and disease profile), improving front-line regimens (e.g. adding newer agents earlier), developing novel small molecules or bispecifics, and seeking approvals in more global markets.<\/p> <\/div> <\/div>\n","protected":false},"excerpt":{"rendered":"<p>Multiple myeloma, a complex blood cancer rooted in the bone marrow, affects 160K people globally each year, with a mortality rate of 106K. According to DelveInsight, nearly 75K new cases were reported across seven major markets in 2023, a figure expected to climb in the coming years. Yet, amid these sobering statistics, a wave of [&hellip;]<\/p>\n","protected":false},"author":20,"featured_media":31406,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[18321,20004,22296,11388,22479,204,410,2833,16670,16669,16671,19906,16672],"industry":[17225],"therapeutic_areas":[17233,17228],"class_list":["post-31405","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-advanced-multiple-myeloma","tag-american-society-of-hematology","tag-bispecific-antibodies","tag-car-t-3","tag-car-t-cell-therapies-for-multiple-myeloma","tag-delveinsight","tag-multiple-myeloma","tag-multiple-myeloma-drugs-market","tag-multiple-myeloma-incidence","tag-multiple-myeloma-market","tag-multiple-myeloma-pipeline","tag-multiple-myeloma-treatment","tag-multiple-myeloma-treatment-market","industry-pharmaceutical","therapeutic_areas-hematological-disorders","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Multiple Myeloma Treatment: Breakthroughs &amp; Future Innovations<\/title>\n<meta name=\"description\" content=\"Discover the latest in multiple myeloma treatment, from SARCLISA approvals to cutting-edge CAR-T therapies, shaping patient care.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/latest-breakthroughs-multiple-myeloma-treatment\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Multiple Myeloma Treatment: Breakthroughs &amp; Future Innovations\" \/>\n<meta property=\"og:description\" content=\"Discover the latest in multiple myeloma treatment, from SARCLISA approvals to cutting-edge CAR-T therapies, shaping patient care.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/latest-breakthroughs-multiple-myeloma-treatment\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-02T11:56:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-26T07:33:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/04\/02172538\/Revolutionary-Advances-and-Bright-New-Horizons-in-Multiple-Myeloma-Treatment.png\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Jatin Vimal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jatin Vimal\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"10 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Multiple Myeloma Treatment: Breakthroughs & Future Innovations","description":"Discover the latest in multiple myeloma treatment, from SARCLISA approvals to cutting-edge CAR-T therapies, shaping patient care.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/latest-breakthroughs-multiple-myeloma-treatment","og_locale":"en_US","og_type":"article","og_title":"Multiple Myeloma Treatment: Breakthroughs & Future Innovations","og_description":"Discover the latest in multiple myeloma treatment, from SARCLISA approvals to cutting-edge CAR-T therapies, shaping patient care.","og_url":"https:\/\/www.delveinsight.com\/blog\/latest-breakthroughs-multiple-myeloma-treatment","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2025-04-02T11:56:39+00:00","article_modified_time":"2025-09-26T07:33:13+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/04\/02172538\/Revolutionary-Advances-and-Bright-New-Horizons-in-Multiple-Myeloma-Treatment.png","type":"image\/png"}],"author":"Jatin Vimal","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Jatin Vimal","Est. reading time":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":["WebPage","FAQPage"],"@id":"https:\/\/www.delveinsight.com\/blog\/latest-breakthroughs-multiple-myeloma-treatment","url":"https:\/\/www.delveinsight.com\/blog\/latest-breakthroughs-multiple-myeloma-treatment","name":"Multiple Myeloma Treatment: Breakthroughs & Future Innovations","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/latest-breakthroughs-multiple-myeloma-treatment#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/latest-breakthroughs-multiple-myeloma-treatment#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/04\/02172538\/Revolutionary-Advances-and-Bright-New-Horizons-in-Multiple-Myeloma-Treatment.png","datePublished":"2025-04-02T11:56:39+00:00","dateModified":"2025-09-26T07:33:13+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158"},"description":"Discover the latest in multiple myeloma treatment, from SARCLISA approvals to cutting-edge CAR-T therapies, shaping patient care.","mainEntity":[{"@id":"https:\/\/www.delveinsight.com\/blog\/latest-breakthroughs-multiple-myeloma-treatment#faq-question-1758871926032"},{"@id":"https:\/\/www.delveinsight.com\/blog\/latest-breakthroughs-multiple-myeloma-treatment#faq-question-1758871936874"},{"@id":"https:\/\/www.delveinsight.com\/blog\/latest-breakthroughs-multiple-myeloma-treatment#faq-question-1758871937509"},{"@id":"https:\/\/www.delveinsight.com\/blog\/latest-breakthroughs-multiple-myeloma-treatment#faq-question-1758871937957"},{"@id":"https:\/\/www.delveinsight.com\/blog\/latest-breakthroughs-multiple-myeloma-treatment#faq-question-1758871938469"}],"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/latest-breakthroughs-multiple-myeloma-treatment"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/latest-breakthroughs-multiple-myeloma-treatment#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/04\/02172538\/Revolutionary-Advances-and-Bright-New-Horizons-in-Multiple-Myeloma-Treatment.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/04\/02172538\/Revolutionary-Advances-and-Bright-New-Horizons-in-Multiple-Myeloma-Treatment.png","width":466,"height":284,"caption":"Revolutionary Advances and Bright New Horizons in Multiple Myeloma Treatment"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158","name":"Jatin Vimal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","caption":"Jatin Vimal"},"sameAs":["https:\/\/www.delveinsight.com"]},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/latest-breakthroughs-multiple-myeloma-treatment#faq-question-1758871926032","position":1,"url":"https:\/\/www.delveinsight.com\/blog\/latest-breakthroughs-multiple-myeloma-treatment#faq-question-1758871926032","name":"What are the most recent major approved therapies for multiple myeloma?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Recent advances include SARCLISA (isatuximab) gaining approval in new indications. For example, in 2024, SARCLISA plus VRd (bortezomib, lenalidomide, dexamethasone) was approved as a first-line treatment for newly diagnosed multiple myeloma (NDMM) patients ineligible for stem cell transplant. Also, therapies such as TECVAYLI, CARVYKTI, and TALVEY, as well as anti-BCMA agents like BLENREP, have enriched the treatment arsenal.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/latest-breakthroughs-multiple-myeloma-treatment#faq-question-1758871936874","position":2,"url":"https:\/\/www.delveinsight.com\/blog\/latest-breakthroughs-multiple-myeloma-treatment#faq-question-1758871936874","name":"What is SARCLISA\u2019s evolving role in multiple myeloma treatment?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"SARCLISA is becoming a key player. Beyond its earlier indication (after \u22652 prior therapies), in September 2024 it was approved in combination with VRd as a first-line regimen for transplant-ineligible NDMM patients. Data from the IMROZ and GMMG-HD7 phase III studies support its ability to deliver deeper and more durable responses when added to standard regimens.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/latest-breakthroughs-multiple-myeloma-treatment#faq-question-1758871937509","position":3,"url":"https:\/\/www.delveinsight.com\/blog\/latest-breakthroughs-multiple-myeloma-treatment#faq-question-1758871937509","name":"What are the most promising upcoming therapies in the multiple myeloma pipeline?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"The pipeline includes various CAR-T therapies, bispecific antibodies, and novel targeted agents. Notable candidates include Anito-Cel (Arcellx), Mezigdomide (BMS \/ Celgene), PHE885 (Novartis), REGN5459 (Regeneron), Descartes-11 (Cartesian Therapeutics), HDP-101 (Heidelberg Pharma), BGB-11417 (Beigene), Zevorcabtagene Autoleucel (Carsgen), CFT7455 (C4 Therapeutics), among others.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/latest-breakthroughs-multiple-myeloma-treatment#faq-question-1758871937957","position":4,"url":"https:\/\/www.delveinsight.com\/blog\/latest-breakthroughs-multiple-myeloma-treatment#faq-question-1758871937957","name":"Which recent clinical trials have shown significant results, and what metrics are being used?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Several trials have delivered important data: CARTITUDE-4 demonstrated that ciltacabtagene autoleucel (Carvykti) induced measurable residual disease (MRD) negativity at a 10\u207b\u2075 threshold in ~69% of evaluable patients by day 56, rising to 86% at six months. The PERSEUS trial showed that D-VRd (daratumumab-VRd) followed by daratumumab\/lenalidomide maintenance improved progression-free survival (PFS) and MRD-negativity compared to VRd + lenalidomide maintenance in transplant-eligible NDMM. This benefit held across different cytogenetic risk groups.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/latest-breakthroughs-multiple-myeloma-treatment#faq-question-1758871938469","position":5,"url":"https:\/\/www.delveinsight.com\/blog\/latest-breakthroughs-multiple-myeloma-treatment#faq-question-1758871938469","name":"What are the biggest challenges and what future directions are emerging?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Challenges include ensuring access to CAR-T therapies world-wide, managing cost, achieving durable responses especially in high-risk patient populations, and optimizing sequencing of therapies. Future directions involve precision medicine approaches (tailoring treatments based on genetic and disease profile), improving front-line regimens (e.g. adding newer agents earlier), developing novel small molecules or bispecifics, and seeking approvals in more global markets.","inLanguage":"en-US"},"inLanguage":"en-US"}]}},"author_meta":{"display_name":"Jatin Vimal","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/jatin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/04\/02172538\/Revolutionary-Advances-and-Bright-New-Horizons-in-Multiple-Myeloma-Treatment-300x183.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Advanced Multiple Myeloma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">American Society of Hematology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Bispecific Antibodies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">CAR T<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">CAR T-cell Therapies for Multiple Myeloma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Multiple Myeloma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Multiple MYELOMA drugs Market.<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Multiple Myeloma Incidence<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Multiple Myeloma Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Multiple Myeloma Pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Multiple Myeloma Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Multiple Myeloma Treatment Market<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Advanced Multiple Myeloma<\/span>","<span class=\"advgb-post-tax-term\">American Society of Hematology<\/span>","<span class=\"advgb-post-tax-term\">Bispecific Antibodies<\/span>","<span class=\"advgb-post-tax-term\">CAR T<\/span>","<span class=\"advgb-post-tax-term\">CAR T-cell Therapies for Multiple Myeloma<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">Multiple Myeloma<\/span>","<span class=\"advgb-post-tax-term\">Multiple MYELOMA drugs Market.<\/span>","<span class=\"advgb-post-tax-term\">Multiple Myeloma Incidence<\/span>","<span class=\"advgb-post-tax-term\">Multiple Myeloma Market<\/span>","<span class=\"advgb-post-tax-term\">Multiple Myeloma Pipeline<\/span>","<span class=\"advgb-post-tax-term\">Multiple Myeloma Treatment<\/span>","<span class=\"advgb-post-tax-term\">Multiple Myeloma Treatment Market<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 1 year ago","modified":"Updated 6 months ago"},"absolute_dates":{"created":"Posted on Apr 2, 2025","modified":"Updated on Sep 26, 2025"},"absolute_dates_time":{"created":"Posted on Apr 2, 2025 5:26 pm","modified":"Updated on Sep 26, 2025 1:03 pm"},"featured_img_caption":"Revolutionary Advances and Bright New Horizons in Multiple Myeloma Treatment\n","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/31405","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=31405"}],"version-history":[{"count":5,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/31405\/revisions"}],"predecessor-version":[{"id":33520,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/31405\/revisions\/33520"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/31406"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=31405"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=31405"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=31405"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=31405"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=31405"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}